Thomas Zander

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.7K citations · Full text

Chemotherapy Versus Chemotherapy, Esophageal Cancer, Gastrointestinal Oncology +7

Comprehensive genomic profiles of small cell lung cancer

Julie George, Jing Lim, Se Jin Jang et al. · Nature · 2015 · 2.3K citations · Full text

Cancer Genomics, Bronchial Neoplasm, Comprehensive Genomic Profiles +3

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Marcin Imieliński, Alice H. Berger, Peter S. Hammerman et al. · Cell · 2012 · 1.8K citations · Full text

Tumor Biology, Engineering, Tumor Heterogeneity +12

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer, Lynnette Fernandez‐Cuesta, Martin L. Sos et al. · Nature Genetics · 2012 · 1.4K citations · Full text

Engineering, Somatic Variant, Tumor Heterogeneity +10